title: Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
abstract: Our objective was to compare lipid profiles of schizophrenic patients treated with conventional antipsychotics or risperidone to those of patients switched to olanzapine. Our results indicate that in patients switched to olanzapine, fasting serum lipids initially increased then returned to pretreatment levels, and endpoint lipid levels were not significantly different from those in patients remaining on conventional antipsychotics or risperidone.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA. bj_kinon@lilly.com
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Kinon
authors.forename: Hong
authors.initials: H
authors.lastname: Liu-Seifert
authors.forename: Jonna
authors.initials: J
authors.lastname: Ahl
authors.forename: Saeeduddin
authors.initials: S
authors.lastname: Ahmed
authors.forename: Robert W
authors.initials: RW
authors.lastname: Baker
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008137:Longitudinal Studies; D000077152:Olanzapine; D011446:Prospective Studies; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D008055:Lipids; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine